We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
Cap. Flow
-$166M
Cap. Flow %
-6.88%
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$54.6M
2
APLT
Applied Therapeutics
APLT
+$33.4M
3
CNC icon
Centene
CNC
+$31.6M
4
BPMC
Blueprint Medicines
BPMC
+$22.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.1M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$106M
2
UNH icon
UnitedHealth
UNH
+$80.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$64.2M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$35.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 95.03%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTX
101
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.75M 0.2%
500,000
– –
TXG icon
102
10x Genomics
TXG
$7.83B
$4.74M 0.2%
76,000
+3,500
+5% +$273K
NGM
103
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.33M 0.18%
351,100
– –
OSW icon
104
OneSpaWorld
OSW
$2.65B
$4.26M 0.18%
1,050,000
+150,000
+17% +$1.8M
ANAB icon
105
AnaptysBio
ANAB
$1.68B
$4.24M 0.18%
300,000
+165,000
+122% +$2.5M
IMVT icon
106
Immunovant
IMVT
$8.34B
$3.89M 0.16%
+250,000
New +$3.76M
MYOV
107
DELISTED
Myovant Sciences Ltd.
MYOV
$3.77M 0.16%
500,000
– –
SYRE icon
108
Spyre Therapeutics
SYRE
$8.99B
$3.73M 0.15%
32,000
– –
PHAS
109
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.72M 0.15%
1,125,000
– –
PASG icon
110
Passage Bio
PASG
$14.3M
$3.54M 0.15%
+11,250
New +$3.52M
OBSV
111
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.37M 0.14%
1,400,000
+610,520
+77% +$1.97M
ADAP
112
DELISTED
Adaptimmune Therapeutics
ADAP
$3.26M 0.14%
1,200,000
+400,000
+50% +$1.33M
AXNX
113
DELISTED
Axonics, Inc. Common Stock
AXNX
$3.18M 0.13%
125,000
-975,000
-89% -$29M
TRIL
114
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.03M 0.13%
+750,000
New +$2.83M
GMDA
115
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.02M 0.12%
1,000,000
– –
CO
116
DELISTED
Global Cord Blood Corporation
CO
$2.94M 0.12%
925,000
– –
GWPH
117
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.63M 0.11%
+30,000
New +$3.18M
ACRS icon
118
Aclaris Therapeutics
ACRS
$870M
$1.66M 0.07%
1,600,000
– –
XLRN
119
DELISTED
Acceleron Pharma
XLRN
$1.57M 0.07%
+17,500
New +$1.36M
MGNX icon
120
MacroGenics
MGNX
$250M
$1.34M 0.06%
230,000
– –
FPRX
121
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$908K 0.04%
400,000
– –
BMY.RT
122
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$704K 0.03%
185,150
– –
NBRV
123
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$604K 0.03%
4,200
-4,200
-50% -$1.28M
CVET
124
DELISTED
Covetrus, Inc. Common Stock
CVET
$168K 0.01%
20,683
– –
BLUE
125
DELISTED
bluebird bio
BLUE
– –
-2,702
Closed -$3.07M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.

  • Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
  • Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
  • Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
  • Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
  • Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.